help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on February 20, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2084
A more recent version of this article appeared on May 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/5/1592    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Resmini, E.
Right arrow Articles by Ferone, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Resmini, E.
Right arrow Articles by Ferone, D.

Submitted on September 22, 2006
Accepted on February 13, 2007

Rapid pituitary tumor shrinkage with dissociation between anti-proliferative and anti-secretory effects of a long-acting octreotide in an acromegalic patient

Eugenia Resmini, Patrizia Dadati, Jean-Luis Ravetti, Gianluigi Zona, Renato Spaziante, Alexandru Saveanu, Philippe Jaquet, Michael D Culler, Federico Bianchi, Alberto Rebora, Francesco Minuto, and Diego Ferone*

Department of Endocrinology & Medical Sciences and Center of Excellence for Biomedical Research (E.R., F.B., A.B., F.M., D.F.), Department of Pathology (P.D., J-L.R.), Department of Neurosurgery (G.Z., R.S.), San Martino Hospital University of Genova, Genova, Italy. Interactions Cellulaires Neuroendocriniennes, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Institut Fédératif Jean Roche (A.S., P.J), Faculté de Médecine Nord, Marseille Cedex, France. Biomeasure Inc./IPSEN (M.D.C), Milford, Massachusetts, USA CLINICAL CASE SEMINAR

* To whom correspondence should be addressed. E-mail: ferone{at}unige.it.

Context: Criteria to define the response to somatostatin analogs (SSA) in acromegaly are based on biochemical control of the disease. However, the mechanisms of action of SSAs in inhibiting tumor growth and hormonal secretion are only partially understood and the two effects may occur independently.

Objective: To investigate the dissociation between anti-proliferative and anti-secretive effects of SSA in an octreotide-resistant patient displaying dramatic tumor shrinkage during primary therapy with octreotide LAR.

Design and setting: We characterized somatostatin and dopamine D2 receptor expression by immunohistochemistry and real-time RT-PCR. The effects of different receptor-selective, bi-specific analogs and chimeric somatostatin/dopamine compounds on GH secretion and cell proliferation in primary cell cultures of the tumor were assessed.

Results: The expression of sst5 and D2R was higher compared to the other receptor subtypes. GH inhibition by SS-14 and by the two chimeric somatostatin/dopamine compounds was scant, but greater than subtype-selective and sst2/sst5 bi-specific agonists. Conversely, cell growth was potently inhibited by all test substances. However, SS-14, sst2/sst5 bi-specific agonist and chimeric molecules were more potent than the other compounds.

Conclusions: The significant antiproliferative effect of octreotide seems to be related to the higher expression of sst5 and the negligible antihormonal effect to the lower expression of sst2. However, activation of multiple receptors by new analogs may produce better control of tumor cell activities. The dissociation between anti-secretive and anti-proliferative effects observed in vivo and in vitro confirms that SSAs may induce tumor shrinkage despite the lack of effect on GH secretion.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar
Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization
Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Ferone, W. W. de Herder, R. Pivonello, J. M. Kros, P. M. van Koetsveld, T. de Jong, F. Minuto, A. Colao, S. W. J. Lamberts, and L. J. Hofland
Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1412 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. F Taboada, R. M Luque, L. V. Neto, E. d. O Machado, B. C Sbaffi, R. C Domingues, J. B Marcondes, L. M C Chimelli, R. Fontes, P. Niemeyer, et al.
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Eur. J. Endocrinol., March 1, 2008; 158(3): 295 - 303.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society